Revlimid

Revlimid is a medicine used for the treatment of certain cancers and serious conditions affecting blood cells and bone marrow, namely multiple myeloma, myelodysplastic syndromes and mantle cell and follicular lymphoma. In **multiple myeloma**, a cancer of a type of white blood cells called plasma cells, Revlimid is used: - in adults who have had a stem cell transplant (a procedure where the patient’s bone marrow is cleared of cells and replaced by stem cells from a donor); - in adults with previously untreated (newly diagnosed) multiple myeloma, who cannot have stem cell transplantation. It is used in combination with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone; - in adults whose disease has been treated at least once. It is used in combination with dexamethasone. In **myelodysplastic syndromes**, a group of bone marrow disorders that cause anaemia (low red blood cell counts), Revlimid is used in patients who need blood transfusions to manage their anaemia. It is used in patients with a genetic abnormality (called deletion 5q) when other treatments are not adequate. In **mantle cell lymphoma** and **follicular lymphoma**, blood cancers that affect a type of white blood cell called B lymphocytes, Revlimid is used in adults whose disease has come back after treatment or does not improve with treatment. In follicular lymphoma it is used with the medicine rituximab. Revlimid contains the active substance lenalidomide.